Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1

Osamu Tomita, Kazutoshi Iijima, Takeshi Ishibashi, Tomoo Osumi, Kenichiro Kobayashi, Hajime Okita, Masahiro Saito, Tetsuya Mori, Toshiaki Shimizu, Nobutaka Kiyokawa

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


We introduced SNX2-ABL1, a novel ABL1-related chimeric transcript lacks SH3 and SH2 domains, into murine Ba/F3 cells and compared their function with that of BCR-ABL1. After the expression of SNX2-ABL1 proteins, Ba/F3 cells acquired an ability to proliferate in an IL-3-independent manner. Upon treatment with both imatinib and dasatinib, BCR-ABL1-expressing Ba/F3 cells underwent rapid apoptosis, whereas SNX2-ABL1-expressing Ba/F3 cells showed poorer sensitivity toward these TKIs and could proliferate in the presence of a low dose of dasatinib. Therefore, other TKIs with a more selective effect against this chimeric kinase should be used for the treatment of patients with SNX2-ABL1+ ALL.

Original languageEnglish
Pages (from-to)361-370
Number of pages10
JournalLeukemia Research
Issue number3
Publication statusPublished - 2014 Mar
Externally publishedYes


  • Acute lymphoblastic leukemia
  • BCR-ABL1
  • Phosphorylation
  • SNX2-ABL1
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1'. Together they form a unique fingerprint.

Cite this